208 related articles for article (PubMed ID: 1678313)
1. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.
Boesch D; Gavériaux C; Jachez B; Pourtier-Manzanedo A; Bollinger P; Loor F
Cancer Res; 1991 Aug; 51(16):4226-33. PubMed ID: 1678313
[TBL] [Abstract][Full Text] [Related]
2. SDZ 280-446, a novel semi-synthetic cyclopeptolide: in vitro and in vivo circumvention of the P-glycoprotein-mediated tumour cell multidrug resistance.
Loor F; Boesch D; Gavériaux C; Jachez B; Pourtier-Manzanedo A; Emmer G
Br J Cancer; 1992 Jan; 65(1):11-8. PubMed ID: 1346365
[TBL] [Abstract][Full Text] [Related]
3. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative.
Boesch D; Muller K; Pourtier-Manzanedo A; Loor F
Exp Cell Res; 1991 Sep; 196(1):26-32. PubMed ID: 1879470
[TBL] [Abstract][Full Text] [Related]
4. Atypical multi-drug resistance (MDR): low sensitivity of a P-glycoprotein-expressing human T lymphoblastoid MDR cell line to classical P-glycoprotein-directed resistance-modulating agents.
Jachez B; Loor F
Anticancer Drugs; 1993 Dec; 4(6):605-15. PubMed ID: 7905300
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists.
Yang JM; Goldenberg S; Gottesman MM; Hait WN
Cancer Res; 1994 Feb; 54(3):730-7. PubMed ID: 7905786
[TBL] [Abstract][Full Text] [Related]
6. SDZ PSC 833 and SDZ 280-446 are the most active of various resistance-modifying agents in restoring rhodamine-123 retention within multidrug resistant P388 cells.
Pourtier-Manzanedo A; Didier AD; Muller CD; Loor F
Anticancer Drugs; 1992 Aug; 3(4):419-25. PubMed ID: 1421439
[TBL] [Abstract][Full Text] [Related]
7. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo.
Watanabe T; Tsuge H; Oh-Hara T; Naito M; Tsuruo T
Acta Oncol; 1995; 34(2):235-41. PubMed ID: 7718262
[TBL] [Abstract][Full Text] [Related]
8. SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia.
Keller RP; Altermatt HJ; Nooter K; Poschmann G; Laissue JA; Bollinger P; Hiestand PC
Int J Cancer; 1992 Feb; 50(4):593-7. PubMed ID: 1347037
[TBL] [Abstract][Full Text] [Related]
9. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833.
Jiang XR; Kelsey SM; Wu YL; Newland AC
Br J Haematol; 1995 Jun; 90(2):375-83. PubMed ID: 7794760
[TBL] [Abstract][Full Text] [Related]
10. Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor.
Friche E; Jensen PB; Nissen NI
Cancer Chemother Pharmacol; 1992; 30(3):235-7. PubMed ID: 1628375
[TBL] [Abstract][Full Text] [Related]
11. Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833.
Michieli M; Damiani D; Michelutti A; Candoni A; Masolini P; Scaggiante B; Quadrifoglio F; Baccarani M
Haematologica; 1994; 79(6):500-7. PubMed ID: 7896208
[TBL] [Abstract][Full Text] [Related]
12. Circumvention of multidrug resistance by a newly synthesized quinoline derivative, MS-073.
Sato W; Fukazawa N; Suzuki T; Yusa K; Tsuruo T
Cancer Res; 1991 May; 51(9):2420-4. PubMed ID: 1673087
[TBL] [Abstract][Full Text] [Related]
13. Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833.
Gonzalez O; Colombo T; De Fusco M; Imperatori L; Zucchetti M; D'Incalci M
Cancer Chemother Pharmacol; 1995; 36(4):335-40. PubMed ID: 7628053
[TBL] [Abstract][Full Text] [Related]
14. Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing the mdr1 phenotype.
te Boekhorst PA; van Kapel J; Schoester M; Sonneveld P
Cancer Chemother Pharmacol; 1992; 30(3):238-42. PubMed ID: 1352739
[TBL] [Abstract][Full Text] [Related]
15. Characterization of four drug-resistant P388 sublines: resistance/sensitivity in vivo, resistance-and proliferation-markers, immunogenicity.
Fichtner I; Stein U; Hoffmann J; Winterfeld G; Pfeil D; Hentschel M
Anticancer Res; 1994; 14(5A):1995-2003. PubMed ID: 7847840
[TBL] [Abstract][Full Text] [Related]
16. Effect of the nonimmunosuppressive cyclosporin analog SDZ PSC-833 on colchicine and doxorubicin biliary secretion by the rat in vivo.
Speeg KV; Maldonado AL
Cancer Chemother Pharmacol; 1994; 34(2):133-6. PubMed ID: 7910787
[TBL] [Abstract][Full Text] [Related]
17. Microfluorometric evaluation of calcein acetoxymethyl ester as a probe for P-glycoprotein-mediated resistance: effects of cyclosporin A and its nonimmunosuppressive analogue SDZ PSC 833.
Liminga G; Nygren P; Larsson R
Exp Cell Res; 1994 Jun; 212(2):291-6. PubMed ID: 7910563
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of P-glycoprotein-mediated vinblastine transport across HCT-8 intestinal carcinoma monolayers by verapamil, cyclosporine A and SDZ PSC 833 in dependence on extracellular pH.
Zacherl J; Hamilton G; Thalhammer T; Riegler M; Cosentini EP; Ellinger A; Bischof G; Schweitzer M; Teleky B; Koperna T
Cancer Chemother Pharmacol; 1994; 34(2):125-32. PubMed ID: 7910786
[TBL] [Abstract][Full Text] [Related]
19. SDZ PSC-833--a novel potent in vitro chemosensitizer in multiple myeloma.
Jonsson B; Nilsson K; Nygren P; Larsson R
Anticancer Drugs; 1992 Dec; 3(6):641-6. PubMed ID: 1363199
[TBL] [Abstract][Full Text] [Related]
20. Reversal of multidrug resistance by a novel quinoline derivative, MS-209.
Sato W; Fukazawa N; Nakanishi O; Baba M; Suzuki T; Yano O; Naito M; Tsuruo T
Cancer Chemother Pharmacol; 1995; 35(4):271-7. PubMed ID: 7828268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
